149 related articles for article (PubMed ID: 19920385)
1. [Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].
Yashiki C; Hirose T; Okuda K; Yamaoka T; Ohnishi T; Adachi M; Nakamura A
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1839-43. PubMed ID: 19920385
[TBL] [Abstract][Full Text] [Related]
2. [Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
Yashiki C; Hirose T; Sugiyama T; Kusumoto S; Shirai T; Ohmori T; Adachi M; Nakamura A
Gan To Kagaku Ryoho; 2010 Feb; 37(2):245-9. PubMed ID: 20154478
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Yoshimura A; Noro R; Miyanaga A; Mizutani H; Kosaihira S; Minegishi Y; Seike M; Hino M; Ando M; Nomura K; Okano T; Kobayashi K; Gemma A;
Anticancer Res; 2012 Oct; 32(10):4473-8. PubMed ID: 23060575
[TBL] [Abstract][Full Text] [Related]
4. Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Charpidou A; Tsagouli S; Tsimpoukis S; Vassias A; Makrilia N; Stratakos G; Gkiozos I; Syrigos K
Anticancer Drugs; 2010 Jul; 21(6):651-5. PubMed ID: 20386306
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
Kim SH; Kim MJ; Kim YJ; Chang H; Kim JW; Lee JO; Lee KW; Kim JH; Bang SM; Lee JS
Medicine (Baltimore); 2017 Oct; 96(42):e8176. PubMed ID: 29049199
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Lee GW; Go SI; Cho YJ; Jeong YY; Kim HC; Duk Lee J; Hwang YS; Ko GH; Lee JH; Kim DC; Yang JW; Oh S; Lee JS
J Thorac Oncol; 2012 Mar; 7(3):528-34. PubMed ID: 22258474
[TBL] [Abstract][Full Text] [Related]
7. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
10. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease.
Yoshida T; Yoh K; Goto K; Niho S; Umemura S; Ohmatsu H; Ohe Y
Anticancer Res; 2013 Mar; 33(3):1175-9. PubMed ID: 23482799
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
[TBL] [Abstract][Full Text] [Related]
17. An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Shao N; Jin S; Zhu W
J Thorac Oncol; 2012 Feb; 7(2):470-2. PubMed ID: 22252565
[No Abstract] [Full Text] [Related]
18. [Evaluation of chemotherapy, especially combined therapy with Carboplatin Plus Etoposide(CE), in patients aged > or =80 years old with extensive-disease small-cell lung cancer].
Tamiya A; Tsuya A; Nakamura Y; Kaira K; Naitou T; Murakami H; Takahashi T; Endo M; Yamamoto N
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1041-4. PubMed ID: 20567104
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.
Lee DH; Kim SW; Suh C; Lee JS; Ahn JS; Ahn MJ; Park K; Na II; Lee JC; Ryoo BY; Yang SH
Cancer; 2010 Jan; 116(1):132-6. PubMed ID: 19904804
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.
Horn L; Zhao Z; Sandler A; Johnson D; Shyr Y; Wolff S; Devore RF; Laskin J
Clin Lung Cancer; 2011 May; 12(3):161-5. PubMed ID: 21663858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
